BioCardia to Present at Maxim Group’s Inaugural Emerging Growth Virtual Conference
BioCardia (Nasdaq: BCDA) announces CEO Dr. Peter Altman will present at the Maxim Group’s Inaugural Emerging Growth Virtual Conference, scheduled for March 17-19, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCardia (Nasdaq: BCDA) announces CEO Dr. Peter Altman will present at the Maxim Group’s Inaugural Emerging Growth Virtual Conference, scheduled for March 17-19, 2021. Dr. Altman's live fireside chat is set for 3:30 PM ET on March 19. Registered attendees can also access a corporate presentation on the conference website and request a 1x1 meeting with Dr. Altman post-conference. BioCardia focuses on developing regenerative therapies for cardiovascular disease, with notable products like the CardiAMP cell therapy and the Helix Biotherapeutic Delivery System.
Details
News Market Reaction – BCDA
The recorded move for BCDA in the trading session of this news was +0.75%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN CARLOS, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, announces that CEO Dr. Peter Altman will present at Maxim Group’s Inaugural Emerging Growth Virtual Conference to be held March 17-19, 2021.
Investors can view Dr. Altman’s live fireside chat presentation at 3:30pm ET on March 19 and once registered for the conference here, can listen to a corporate presentation which will be available on the conference website. Investors can also request a 1x1 meeting with Dr. Altman to be arranged following the conclusion of the conference.
About BioCardia
BioCardia, headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and respiratory disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company’s biotherapeutic platforms in clinical development. The Company's products include the Helix Biotherapeutic Delivery System and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix system and clinical support for their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia, and acute myocardial infarction. For more information, visit www.BioCardia.com.
INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@BioCardia.com
(650) 226-0120
MEDIA CONTACT:
Michelle McAdam, Chronic Communications, Inc.
michelle@chronic-comm.com
(310) 545-6654
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.